Skip to main content Accessibility help
×
Home

EPA-0627 - Safety Profile of Methylphenidate Hydrochloride-Modified Release (MPH-LA) in Adults and Children with Attention Deficit Hyperactivity Disorder

  • Y. Ginsberg (a1), T. Arngrim (a2), A. Philipsen (a3), P. Gandhi (a4), CW. Chen (a5), V. Kumar (a5) and M. Huss (a6)...

Abstract

Introduction and objectives:

The safety profile of MPH-LA in the paediatric population has been well studied. However, there are very limited studies reporting safety of MPH-LA in adults. We present the safety profile of MPH-LA in adults and from a pooled analysis in children.

Methods:

Data from 3 multiple-dose, double-blind, placebo-controlled studies of 7-12 weeks duration in children with ADHD; MPH-LA (10-80mg/d) (n=314) & placebo (n=318) (aged 6-12 yrs in 2 studies &13-17 yrs in one study) were pooled for this analysis. In addition, data from 722 adult patients, 18-60 yrs of age with ADHD receiving MPH-LA 40-80 mg/d (n=542) or placebo (n=180) from double-blind dose confirmation phase of 9-week duration from one study was included in the analysis.

Results:

Common adverse events (AEs) reported by both adult and paediatric ADHD patients were decreased appetite, headache, nasopharyngitis, nausea, and insomnia (Table). Incidence of serious AEs (SAEs) was low with MPH-LA in both adults (0.7%) and children (0.6%) compared with placebo group (1.1% in adults and 0.3% in children).

Conclusions:

Our findings show that safety profile of MPH-LA in adults is similar to that observed in the paediatric population.

Table

Adverse events (>5%) by preferred term in multiple dose, placebo-controlled studies In adult and paedlatrlc ADHD patients

 AdultsChildren
Most common AEsMPH-LA N=542, n (%)Placebo N=1B0, n (%)MPH-LA N=314, n (%)Placebo N=31S, n (%)
Total number of patients with anyAE401 (74.0)108 (60.0)132 (42.0)112(35.2)
YDecreased appetite136(25.1)8 (4.4)30(9.6)5(1.6)
YHeadache111 (20.5)30 (16.7)37 (11.8)32 (10.1)
YDry mouth110(20.3)4(2.2)00
YNausea58 (10.7)9(5.0)12 (3.8)4 (1.3)
YNasopharyngitis54 (10.0)17(9.4)13(4.1)15 (4.7)
YInsomnia44 (8.1)7(3.9)8 (2.5)4(1.3)
YHyperhidrosis43(7.9)5(2.8)00
YPalpitations39(7.2)1 (0.6)00
YFatigue38(7.0)11 (6.1)5(1.6)4(1.3)
YDizziness32 (5.9)5(2.8)5(16)1 (0.3)
YIrritability32(5.9)8 (4.4)4(1.3)1 (0.3)
YAnxiety29(5.4)1 (0.6)3(1.0)0
YInitial insomnia28(5.2)2(1.1)5(1.6)5(1.6)

Analysis data set: Safety population of double-blind dose confirmation phase of 9-week duration conducted in adult ADHD patients and pooled safety population from 3 paediatric studies.

Copyright

EPA-0627 - Safety Profile of Methylphenidate Hydrochloride-Modified Release (MPH-LA) in Adults and Children with Attention Deficit Hyperactivity Disorder

  • Y. Ginsberg (a1), T. Arngrim (a2), A. Philipsen (a3), P. Gandhi (a4), CW. Chen (a5), V. Kumar (a5) and M. Huss (a6)...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.

EPA-0627 - Safety Profile of Methylphenidate Hydrochloride-Modified Release (MPH-LA) in Adults and Children with Attention Deficit Hyperactivity Disorder

  • Y. Ginsberg (a1), T. Arngrim (a2), A. Philipsen (a3), P. Gandhi (a4), CW. Chen (a5), V. Kumar (a5) and M. Huss (a6)...
Submit a response

Comments

No Comments have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *